[go: up one dir, main page]

RS59462B1 - Polipeptidi - Google Patents

Polipeptidi

Info

Publication number
RS59462B1
RS59462B1 RSP20191341A RS59462B1 RS 59462 B1 RS59462 B1 RS 59462B1 RS P20191341 A RSP20191341 A RS P20191341A RS 59462 B1 RS59462 B1 RS 59462B1
Authority
RS
Serbia
Prior art keywords
polypeptides
Prior art date
Application number
Other languages
English (en)
Inventor
Gustav Gaudernack
Anne-Marie Rasmussen
Else Marit Inderberg Suso
Original Assignee
Ultimovacs As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimovacs As filed Critical Ultimovacs As
Publication of RS59462B1 publication Critical patent/RS59462B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RSP20191341 2010-02-16 2011-02-15 Polipeptidi RS59462B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10250265 2010-02-16
PCT/EP2011/000980 WO2011101173A1 (en) 2010-02-16 2011-02-15 Polypeptides
EP11707345.2A EP2536830B1 (en) 2010-02-16 2011-02-15 Polypeptides

Publications (1)

Publication Number Publication Date
RS59462B1 true RS59462B1 (sr) 2019-11-29

Family

ID=42283642

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP20191341 RS59462B1 (sr) 2010-02-16 2011-02-15 Polipeptidi

Country Status (16)

Country Link
US (5) US9657068B2 (sr)
EP (2) EP2536830B1 (sr)
JP (2) JP6042211B2 (sr)
KR (2) KR20130024888A (sr)
CN (2) CN102858964B (sr)
CY (1) CY1122178T1 (sr)
DK (1) DK2536830T3 (sr)
ES (1) ES2751092T3 (sr)
HR (1) HRP20191852T8 (sr)
LT (1) LT2536830T (sr)
PL (1) PL2536830T3 (sr)
PT (1) PT2536830T (sr)
RS (1) RS59462B1 (sr)
RU (1) RU2581800C2 (sr)
SI (1) SI2536830T1 (sr)
WO (1) WO2011101173A1 (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
RU2581800C2 (ru) 2010-02-16 2016-04-20 Ультимовакс Ас Полипептиды
KR102041381B1 (ko) * 2012-03-12 2019-11-27 젬백스 에이에스 능동적인 면역치료법을 이용한 비-소세포성 폐암의 치료
EP2639299A1 (en) * 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
CN104507489B (zh) 2012-05-11 2016-07-13 杰姆维克斯&凯尔有限公司 用于预防和治疗类风湿性关节炎的组合物
WO2013167298A1 (en) * 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
EP3333180B1 (en) * 2012-05-11 2019-08-21 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI616531B (zh) 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
CN110064056B (zh) * 2012-09-19 2022-10-28 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
ES2956510T3 (es) * 2012-09-19 2023-12-22 Gemvax & Kael Co Ltd Péptido penetrante celular, conjugado que lo comprende y composición que comprende el conjugado
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
ES2927473T3 (es) * 2013-06-07 2022-11-07 Gemvax & Kael Co Ltd GV1001, gemcitabina y capecitabina para su uso en el tratamiento del cáncer de páncreas en pacientes con un nivel inicial de eotaxina elevado
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
PH12018502667A1 (en) * 2013-10-23 2022-11-14 Gemvax And Kael Co Ltd Composition for treating and preventing benign prostatic hyperplasia
WO2015072750A1 (ko) * 2013-11-12 2015-05-21 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
JP6553605B2 (ja) * 2013-11-22 2019-07-31 ジェムバックス アンド カエル カンパニー，リミティド 血管新生抑制活性を有するペプチド、及びそれを含む組成物
KR20240073156A (ko) * 2013-12-10 2024-05-24 주식회사 젬백스앤카엘 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
KR102314231B1 (ko) 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
JP6466971B2 (ja) 2014-04-30 2019-02-06 ジェムバックス アンド カエル カンパニー，リミティド 臓器、組織又は細胞移植用組成物、キット及び移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
CN107667112B (zh) 2015-05-26 2021-12-07 珍白斯凯尔有限公司 新型肽和含有其的组合物
JP6923453B2 (ja) * 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
US9937247B2 (en) 2016-02-23 2018-04-10 Maurizio Zanetti Universal cancer vaccine
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
WO2017207814A1 (en) 2016-06-02 2017-12-07 Ultimovacs As A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
CN106267409B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物治疗反应器
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
EP4351634A2 (en) 2021-06-09 2024-04-17 Ultimovacs AB A conjugate
WO2024083866A1 (en) 2022-10-17 2024-04-25 Ultimovacs Asa Cancer treatment
WO2024126758A2 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide
WO2024126737A1 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A core and a conjugate
WO2024153644A1 (en) * 2023-01-16 2024-07-25 Ospedale San Raffaele S.R.L. T-cell receptors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5695100A (en) 1996-07-19 1997-12-09 O'brien; Vincent E. Baby backpack sun/rain shade device
JP3869092B2 (ja) 1996-10-01 2007-01-17 ジェロン・コーポレーション ヒトテロメラーゼ触媒性サブユニット
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6767719B1 (en) 1997-11-26 2004-07-27 Geron Corporation Mouse telomerase reverse transcriptase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US20050013825A1 (en) 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
AU748442B2 (en) 1997-07-01 2002-06-06 Cambia Vertebrate telomerase genes and proteins and uses thereof
AU1785099A (en) * 1998-01-08 1999-07-26 Chugai Seiyaku Kabushiki Kaisha Novel gene having reverse transcriptase motif
JP2002500040A (ja) 1998-01-12 2002-01-08 コールド スプリング ハーバー ラボラトリー 細胞の寿命の延長、方法および試薬
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
EP1126872B1 (en) * 1998-10-29 2006-12-13 Dana-Farber Cancer Institute, Inc. CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
JP2002530436A (ja) 1998-11-25 2002-09-17 ジェネティカ インコーポレイテッド 増殖能を増強しかつ複製老化を防止する方法及び試薬
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
GB0112342D0 (en) 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
WO2003038047A2 (en) 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
US20030166270A1 (en) 2001-11-15 2003-09-04 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for reversibly inducing continual growth in normal cells
US20030232409A1 (en) 2002-03-11 2003-12-18 Regents Of The University Of Minnesota Immortal porcine cells
WO2003095605A2 (en) 2002-05-08 2003-11-20 Pharmacia Italia Spa A chimeric reverse transcriptase and methods for identifying telomerase inhibitors
WO2004002408A2 (en) 2002-06-27 2004-01-08 Geron Corporation Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
CA2504451A1 (en) 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US20090304640A1 (en) 2005-04-27 2009-12-10 Cellixe Pty Ltd Transfection of Collagen-Producing Cells
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
EP1993597A4 (en) 2006-01-19 2010-02-17 Univ California hTERT PEPTIDE
CN101679475B (zh) 2006-07-28 2015-08-12 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
EP1994942A1 (en) 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
US20090142408A1 (en) 2007-07-23 2009-06-04 Telomolecular Corporation Telomerase delivery by biodegradable Nanoparticle
US8362209B2 (en) 2007-08-23 2013-01-29 University Of Medicine And Dentistry Of New Jersey Telomerase reverse transcriptase variant
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
WO2010003520A2 (en) * 2008-06-16 2010-01-14 Genovax S.R.L. Anti-tumor immunotherapy
US8252282B2 (en) 2008-06-19 2012-08-28 University Of Medicine & Dentistry Of New Jersey Nuclear telomerase reverse transcriptase variant
US20110243910A1 (en) 2008-08-12 2011-10-06 Japan Health Sciences Foundation mammalian rna dependent rna polymerase
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
KR101372966B1 (ko) 2009-01-23 2014-03-13 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 표적 세포 유도용 피더 세포
RU2581800C2 (ru) * 2010-02-16 2016-04-20 Ультимовакс Ас Полипептиды
JP5894914B2 (ja) 2010-05-31 2016-03-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍細胞の作製方法
ES2590461T3 (es) 2010-07-02 2016-11-22 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii La transcriptasa inversa de la telomerasa como protección frente al envejecimiento
WO2017207814A1 (en) 2016-06-02 2017-12-07 Ultimovacs As A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Also Published As

Publication number Publication date
LT2536830T (lt) 2019-11-11
RU2581800C2 (ru) 2016-04-20
KR102035199B1 (ko) 2019-10-22
JP6444336B2 (ja) 2018-12-26
HRP20191852T8 (hr) 2021-10-01
JP2013519385A (ja) 2013-05-30
CN102858964B (zh) 2018-10-02
JP2016183169A (ja) 2016-10-20
US20200121771A1 (en) 2020-04-23
KR20180088756A (ko) 2018-08-06
CN108383894A (zh) 2018-08-10
US20130129760A1 (en) 2013-05-23
US20230277641A1 (en) 2023-09-07
CY1122178T1 (el) 2020-11-25
JP6042211B2 (ja) 2016-12-14
PL2536830T3 (pl) 2020-02-28
US20170232087A1 (en) 2017-08-17
US20170232088A1 (en) 2017-08-17
DK2536830T3 (da) 2019-10-21
CN102858964A (zh) 2013-01-02
US10383928B2 (en) 2019-08-20
EP2536830B1 (en) 2019-07-17
ES2751092T3 (es) 2020-03-30
PT2536830T (pt) 2019-10-29
US9657068B2 (en) 2017-05-23
KR20130024888A (ko) 2013-03-08
US11998595B2 (en) 2024-06-04
WO2011101173A1 (en) 2011-08-25
HRP20191852T1 (hr) 2019-12-27
RU2012139432A (ru) 2014-03-27
EP2536830A1 (en) 2012-12-26
EP3581649A1 (en) 2019-12-18
SI2536830T1 (sl) 2019-12-31
US11529403B2 (en) 2022-12-20

Similar Documents

Publication Publication Date Title
HK1182719A1 (en) Polypeptides
RS59462B1 (sr) Polipeptidi
DK3342786T3 (en) Anti-dll3-antistof
AP3107A (en) 5-Alkynyl-pyrimidines
ZA201309174B (en) Polypeptides
IL222301A0 (en) Protease-activatable pore-forming polypeptides
EP2566479A4 (en) AZA-INDAZOLES
EP2640189A4 (en) 3-deutero-pomalidomide
DK3466977T3 (en) Anti-vla-4-antistoffer
GB201012651D0 (en) Peptides
EP2641891A4 (en) PKC ACTIVATOR-
GB201018480D0 (en) Factors
GB201016494D0 (en) Polypeptide
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4937P (en) FlatinsulGL Myoporum insulare
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4536P (en) TB01 Tibouchina urvilleana
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
HUE047406T2 (hu) Polipeptidek
GB201003906D0 (en) Binding polypeptides
GB201008108D0 (en) Helisuacer III
GB201005840D0 (en) Multi-catch pro
GB201003907D0 (en) Detecting polypeptides
AU2010278V (en) Little Tuffy Lomandra confertifolia
GB201010202D0 (en) Fusion polypeptides